C ARL ICAHN owns 1.4% of Illumina, a genomics giant with a market value of $34bn. Mr Icahn’s modest stake belies his ambition. As the elder statesman of activist investing, the 87-year-old aims to convert small shareholdings into considerable influence. Mr Icahn has nominated three directors to the board of Illumina, whose share price has fallen by 60% since its peak in 2021, in part owing to hubristic dealmaking. On May 25th, after The Economist was published, Mr Icahn’s colourful campaign against the firm’s bosses (16 letters, drawing on Shakespeare and Lincoln) will reach a climax at its annual general meeting. It is one of the hottest tickets in this year’s “proxy season”, when most American firms elect their boards of directors.
C Arl Icahn拥有Illumina的1.4％，Illumina是一家基因组巨头，市场价值为340亿美元。伊坎先生的谦虚利益掩盖了他的野心。作为激进投资的年长政治家，这位87岁的年轻人旨在将小额股权转变为相当大的影响力。伊坎先生已提名Illumina董事会的三名董事，自2021年达到顶峰以来，其股价下跌了60％，部分原因是由于狂热的交易。5月25日，经济学家出版后，伊坎先生针对该公司的老板进行了丰富多彩的运动（16封信，用莎士比亚和林肯借鉴）将在年度股东大会上达到高潮。当大多数美国公司选举其董事会时，这是今年“代理季节”中最热门的门票之一。
